سعر ريزينوكاتن 454 جرام باودر 2025

Sodium polystyrene sulfonate cation-exchange resin powder (454 g) for oral or rectal suspension, used to treat hyperkalemia.

• Treatment of hyperkalemia (not for emergency treatment of life-threatening hyperkalemia because of delayed onset).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Anorexia, constipation, diarrhea, fecal impaction, bezoars, ischemic colitis, nausea, vomiting, gastric irritation; systemic alkalosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to polystyrene sulfonate resins; obstructive bowel disease; neonates with reduced gut motility.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Intestinal necrosis and other serious GI events (bleeding, ischemic colitis, perforation), mostly with concomitant sorbitol.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Electrolyte disturbances including severe hypokalemia; fluid overload in patients sensitive to sodium; risk of aspiration.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Other oral medications (e.g., lithium, thyroxine)Resin may bind oral drugs and reduce absorption; separate by at least 3 hours.DailyMed (U.S. National Library of Medicine)
• SorbitolConcomitant use may contribute to intestinal necrosis; not recommended.DailyMed (U.S. National Library of Medicine)
• Cation-donating antacidsMay reduce potassium exchange and increase risk of systemic alkalosis.DailyMed (U.S. National Library of Medicine)

• Not absorbed systemically after oral or rectal use; maternal use is not expected to result in fetal risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Sodium polystyrene sulfonate: Exchanges sodium for potassium in the gut (in vitro ~3.1 mEq, in vivo ~1 mEq K+ per gram); about 4.1 mEq sodium per gram.